James L. Januzzi
Inserm
4 papers in the Anchorcite directory, published between 2013 and 2021, cited 29,464 times in total.
ORCID profileResearch topics
- Heart Failure Treatment and Management · 3 papers
- Cardiovascular Function and Risk Factors · 2 papers
- Diabetes Treatment and Management · 2 papers
- Cardiac pacing and defibrillation studies · 1 paper
- Acute Myocardial Infarction Research · 1 paper
- Cardiac Imaging and Diagnostics · 1 paper
Frequent co-authors
- Javed Butler · 3 papers
- Milton Packer · 2 papers
- Stefan D. Anker · 2 papers
- Gerasimos S Filippatos · 2 papers
- Stuart Pocock · 2 papers
- Peter E. Carson · 2 papers
- Subodh Verma · 2 papers
- Hiroyuki Tsutsui · 2 papers
Papers
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of the American College of Cardiology · 2013 · 12,687 citations
Introduction 1.1. Methodology and Evidence ReviewThe recommendations listed in this document are, whenever possible, evidence based.An extensive evidence review was conducted through October 2011 and includes selected other references through April 2013.Searches were extended to studies, reviews, and other evidence…
- Fourth universal definition of myocardial infarction (2018)European Heart Journal · 2018 · 6,098 citations
... ... ... ... In the late 19th century, post-mortem examinations demonstrated a possible relationship between thrombotic occlusion of a coronary artery and myocardial infarction (MI).1 However, it was not until the beginning of the 20th century that the first…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).